Saratoga Health & Biotechnology Portfolio Fund Class Institutional SBHIX

Morningstar Medalist Rating
  • NAV / 1-Day Return$31.01  /  −0.58%
  • Fund Size$12.4M
  • Adjusted Expense Ratio2.600%
  • Net Expense Ratio2.530%
  • Fee Level: DistributionHigh
  • Share Class TypeInstitutional
  • Morningstar CategoryHealth
  • Equity Style Box (Funds)Mid Value
  • Minimum Initial Investment$250
  • Investment StatusOpen
  • TTM Yield0.00%
  • Turnover Ratio13%

Morningstar’s Analysis SBHIX

Will SBHIX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Saratoga Health & Biotechnology I holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SBHIX

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings50.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Amgen Inc

5.93660,506
Healthcare

Jazz Pharmaceuticals PLC

5.69634,596
Healthcare

United Therapeutics Corp

5.64628,592
Healthcare

McKesson Corp

5.29589,983
Healthcare

Cardinal Health Inc

5.05562,702
Healthcare

Exelixis Inc

4.95551,682
Healthcare

Regeneron Pharmaceuticals Inc

4.56508,041
Healthcare

Cencora Inc

4.53505,321
Healthcare

Medpace Holdings Inc

4.42493,102
Healthcare

Johnson & Johnson

4.32481,827
Healthcare

Sponsor Center